Compliance & Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical, legal, regulatory, or professional advice. The compounds discussed are research chemicals not approved for human consumption by the US FDA, European Medicines Agency (EMA), UK MHRA, Australian TGA, Health Canada, or any other major regulatory authority. They are sold strictly for laboratory research use. WolveStack does not employ medical staff, does not diagnose, treat, or prescribe, and makes no health claims under FTC, UK ASA, EU MDR/UCPD, or AU TGA standards. Always consult a licensed healthcare professional in your jurisdiction before considering any peptide protocol. This site contains affiliate links (FTC 2023 endorsement guidelines compliant); we may earn a commission on qualifying purchases at no additional cost to you. Some compounds discussed are on the WADA prohibited list — competitive athletes should verify current status with their governing body before any research use. Use of research chemicals may be illegal in your jurisdiction.

IMPORTANT: This compound is currently on the World Anti-Doping Agency (WADA) prohibited list. Competitive athletes face sanctions for use including in retirement testing programs. Verify current WADA status with your sport's governing body before any research involvement.

Reviewed by: WolveStack Research Team
Last reviewed: 2026-04-28
Editorial policy

Editorial review process: WolveStack Research Team — collective expertise in peptide pharmacology, regulatory science, and research literature analysis. We synthesize peer-reviewed studies, regulatory filings, and clinical trial data; we do not provide medical advice or treatment recommendations. Content is reviewed and updated as new evidence emerges.

Medical Disclaimer

This article is for informational and educational purposes only and does not constitute medical advice. The compounds discussed are research chemicals that are not FDA-approved for human use. Always consult a licensed healthcare professional before considering any peptide protocol. WolveStack has no medical staff and does not diagnose, treat, or prescribe. See our full disclaimer.

CJC-1295 with DAC is administered as a 1-2 mg subcutaneous injection once or twice weekly via 27-29 gauge insulin syringe needle into subcutaneous tissue of the abdomen, thigh, or shoulder. Subcutaneous (not intramuscular) injection depth is critical—approximately 0.25-0.5 inches into the fatty layer, achieved by pinching skin and injecting at 45-90 degree angle. Injection sites must be rotated systematically (left abdomen Monday, right abdomen Friday, alternating thighs, shoulders) to prevent lipodystrophy (tissue damage, indentations, nodules). Evening or pre-bedtime dosing (30-60 minutes before sleep) is optimal to align with natural sleep-phase GH elevation and enhance sleep quality. Sterile 70% isopropyl alcohol prep of injection site (allow to dry completely) and fresh sterile needle/syringe are essential to prevent bacterial infection. Post-injection massage (30 seconds) improves absorption and reduces irritation.

Injection Site Selection and Rotation

CJC-1295 DAC is administered via subcutaneous injection—into the fatty tissue just beneath the skin but above the muscle. Common injection sites include: abdomen (most popular due to ample subcutaneous tissue and convenience), thighs (quadriceps and lateral thigh), shoulders (deltoid region), or glutes (gluteal region). Subcutaneous injection is preferable to intramuscular injection because CJC-1295 DAC is a peptide hormone that doesn't require deep muscle penetration for efficacy; subcutaneous injection provides reliable absorption with less tissue trauma.

Rotation of injection sites is essential to prevent lipodystrophy (damage to fat tissue causing fatty deposits, indentations, or nodules). A typical rotation pattern: abdomen Monday, thigh Thursday (if twice-weekly). Within each site, rotate specific locations—left abdomen one week, right abdomen the next. This distributes injections across tissue areas, preventing accumulation of scar tissue or inflammation. Users who consistently inject the same location report post-injection soreness, firmness, or visible bumps—signs of localized tissue irritation. Proper rotation eliminates these issues.

Needle Selection and Injection Depth

Needle gauge and length matter for subcutaneous injection. Standard CJC-1295 DAC injection employs 27-29 gauge insulin needles (standard 0.5 inch length) or small-gauge hypodermic needles. These gauges are thin enough to minimize pain and tissue trauma while thick enough to reliably penetrate skin. Gauge 30 or thinner risks clogging with dried peptide; gauges thicker than 25 may cause excessive tissue damage.

Injection depth: approximately 0.25-0.5 inches subcutaneously, visible as a "tent" of skin pulled up when the needle penetrates. The goal is to deposit CJC-1295 DAC in subcutaneous fat, not intramuscularly (which would be deeper) or intradermally (which would be shallower, causing visible bumps and poor absorption). Most users find a 0.5 inch needle length achieves proper depth when angled 45-90 degrees into a pinched skin fold. Pinching the skin creates a thicker target, making it easier to inject subcutaneously without accidentally going intramuscular.

Preparation and Sterile Technique

Before injection, hands should be washed thoroughly. The injection site should be cleaned with a 70% isopropyl alcohol swab, allowed to dry completely (critical—injecting into wet alcohol causes pain and reduces efficacy). The CJC-1295 DAC reconstituted solution should be clear and colorless; any discoloration, cloudiness, or visible particles indicates contamination and should not be injected. The needle and syringe should be sterile (new needle/syringe for each injection, not reused).

Proper sterile technique prevents bacterial infection, which can cause localized infections (redness, swelling, warmth, drainage) or systemic infections in severe cases. The entire injection process—from solution handling to needle insertion to post-injection site care—must prioritize sterility. After injection, the site can be covered with a small bandage if bleeding occurs, though this is rare. Hand washing after injection completes the process.

Dosing Schedule and Timing

Standard dosing is 1-2 mg per injection, once or twice weekly. Weekly dosing (2 mg once per week, typically Monday or Thursday) is most convenient and achieves steady-state by week 3-4. Twice-weekly dosing (1 mg Monday and Thursday) maintains slightly more stable levels throughout the week and may reduce side effect variability, though outcomes are similar. Most users prefer weekly dosing for simplicity.

Timing within the day matters. Evening or pre-bedtime injection (30-60 minutes before sleep) is optimal because it aligns CJC-1295 DAC stimulation with natural sleep-phase GH elevation, enhancing sleep quality. Morning injection produces anabolic effects but doesn't optimize the sleep window. Some users employ randomized timing (different time each week) to prevent circadian adaptation, though data doesn't strongly support this practice. The main consideration is consistency—weekly at the same time each week is simpler than varying schedules.

Fasted vs. Fed State and Absorption

Peptide absorption is not significantly affected by food intake the way some oral medications are (peptides don't enter through the gastrointestinal tract). However, some evidence suggests fasted or early-fasting state (at least 3 hours post-meal) allows slightly faster absorption into circulation. Practically, injection timing relative to meals is a minor optimization; the more important factor is consistency and proper subcutaneous placement.

Many users inject in the evening before bed, when they haven't eaten for several hours, naturally achieving fasted-state injection. Others inject in the morning on an empty stomach. The effect difference is minimal. What matters more is injection frequency and dosing consistency, not meal timing.

Post-Injection Care and Common Issues

After injection, minor post-injection soreness, redness, or small bruising can occur, especially with initial injections. This is normal and resolves within hours. Persistent redness, swelling, warmth, or discharge indicates infection and warrants medical attention. To minimize post-injection soreness: ensure proper depth (avoiding dermis and muscle), use fresh needles, employ proper sterile technique, and rotate sites adequately.

Ice application for 30 seconds pre-injection can reduce pain perception. Massaging the injection site post-injection improves absorption and reduces localized irritation. Some users report that injection angle (more perpendicular vs. 45-degree) affects post-injection soreness; testing both approaches can identify personal preference.

Traveling and Injectable Administration

Traveling with CJC-1295 DAC requires planning. The reconstituted solution must remain refrigerated (2-8°C, standard refrigerator temperature) and shouldn't exceed ~14 days at room temperature (though most practitioners recommend refrigeration for full stability). When traveling: pack reconstituted CJC-1295 DAC in an insulated travel cooler with ice packs, keep it away from extreme heat or direct sunlight, and maintain refrigeration at destination. Many hotels provide mini-fridges upon request.

Syringes, needles, and vials can be packed in checked luggage without issue (syringes with needles pre-attached to vials must be in checked luggage, not carry-on, per TSA rules). For international travel, research destination-country regulations on peptide importation; CJC-1295 is legal in most Western countries as a research chemical but regulations vary.

Injection Frequency Adjustment and Troubleshooting

If weekly 2 mg injections produce side effects (excessive water retention, joint aches) some users reduce to 1 mg twice-weekly, maintaining total weekly dose but spreading it. This distributes GH elevation more evenly, potentially reducing peak side effects while maintaining steady-state GH. Conversely, if weekly injection is missed, don't "double up" the next week; simply resume normal schedule. Missing one injection delays steady-state but doesn't require compensation dosing.

Some users report injection-site specific reactions—one area causing soreness while another is painless. This usually reflects injection depth or technique variation at that site. Reviewing injection technique at problem sites (shallower vs. deeper needle angle, slower injection speed) often resolves localized reactivity.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Particle Peptides

Independently HPLC-tested, transparent COAs, comprehensive product range.

Browse Particle Peptides →

Limitless Life Nootropics

Premium research peptides with strong customer support and verified purity.

Browse Limitless Life →

Frequently Asked Questions on Injection

Can I inject intramuscularly instead of subcutaneously?

Intramuscular injection of CJC-1295 DAC is not recommended. Subcutaneous injection is standard and effective; IM injection may alter absorption kinetics and increase localized tissue damage.

How long does post-injection soreness last?

Minor soreness typically resolves within 2-4 hours. If soreness persists beyond 24 hours, it suggests technique issue (injection depth, site trauma). Severe swelling or heat suggests infection requiring medical attention.

Should I massage the injection site after injecting?

Gentle massage (30 seconds to 1 minute) post-injection improves absorption and reduces localized irritation. Avoid aggressive massage.

Can I use the same syringe/needle twice?

No. Reusing syringes and needles creates infection risk and dulls the needle, causing tissue trauma. Each injection requires fresh sterile equipment.

What if I accidentally inject intradermally?

Intradermal injection (too shallow, into the skin itself) produces visible bumps and irritation but isn't dangerous. Absorption may be slower. Future injections at proper depth resolve the issue.

How do I know if I've hit a blood vessel?

If blood fills the syringe when aspirating (pulling back on the plunger), you've hit a vessel. Withdraw the needle, use a fresh syringe/needle, and inject at a different angle. It's rare with proper subcutaneous depth.

Home Start Here Calculator Vendors About Disclosure Privacy Terms

© 2026 WolveStack. For research and educational purposes only.

WolveStack publishes research summaries for educational purposes only. Nothing here constitutes medical advice. All peptides discussed are for research use only. Consult a qualified healthcare professional before use.